FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Classic Hodgkin Lymphoma in the Older Adult: What's New? PMID 41708412 · Hematol Oncol Clin North Am · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Clinical protocol for the K-3 trial: a single-center, patient-blinded, randomized clinical trial addressing anesthesiologic, oncological and patient recovery outcomes of standard flank approach vs supine approach for robot-assisted partial nephrectomy. PMID 41707608 · Surg Oncol · 2026-Apr 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma. PMID 41704058 · Br J Haematol · 2026-Apr The record describes a randomized, multicentre trial with a primary EFS endpoint and formal results, but the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. Phase classification cannot be established from the abstract alone. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Low-dose fractionated radiotherapy combined with induction chemotherapy in high-risk nasopharyngeal carcinoma: An open-label, randomized phase 2 trial. PMID 41702154 · Oral Oncol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Radiotherapy with twice weekly Gemcitabine and Cisplatin compared to Cisplatin alone for organ preservation in muscle-invasive bladder cancer: results of the GETUG V04 randomized phase II trial. PMID 41690405 · Radiother Oncol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis. PMID 41689889 · Lung Cancer · 2026-Apr The report is a subset analysis (Asian participants) of the MARIPOSA trial. While the analysis itself has formal results, it is not the primary report of the Phase III/definitive trial; it is a secondary/subgroup analysis. The original MARIPOSA trial is likely Phase III (based on drug names and standard trial design for approval), but the report's own metadata does not explicitly confirm the phase of the MARIPOSA trial itself. Therefore, phase3_or_definitive cannot be confirmed from this record alone. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Optimal adjuvant intravesical therapy for intermediate risk non-muscle invasive bladder cancer; oncological and patient-reported outcomes of randomized controlled trial. PMID 41689868 · Urol Oncol · 2026-Apr The record is a randomized, oncology trial with drug intervention and key time-to-event endpoints (RFS, PFS) reported via Kaplan-Meier. However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided information, which is a required criterion for eligibility. Therefore, eligibility cannot be confirmed. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Participation in lung cancer biospecimen studies: an analysis of the ECOG-ACRIN phase 3 E1505 and E5508 clinical trials. PMID 41666849 · Lung Cancer · 2026-Apr The record is a secondary analysis of participation in biospecimen studies within two phase 3 lung cancer therapeutic trials. While the parent trials are oncology, human, randomized, phase 3, and drug-interventional, this specific publication does not report original trial efficacy results or any time-to-event endpoints. It focuses on factors associated with patient consent for biospecimen collection, making it a secondary/sociological analysis rather than a primary efficacy report eligible for Kaplan-Meier digitization. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Long-term oncological outcomes following algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection: a post-hoc analysis of a nationwide, stepped-wedge cluster-randomised trial. PMID 41662856 · Lancet Gastroenterol Hepatol · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Modified EXTREME regimen versus modified TPEx regimen as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, open-label, randomized, exploratory study (TEMPER study). PMID 41661417 · Int J Clin Oncol · 2026-Apr The study is an oncology, human, randomized trial with drug intervention and time-to-event endpoints (PFS, OS). However, the trial is explicitly described as an 'exploratory study' and no Phase III/IIIb or Phase II/III designation is provided in the title, abstract, or metadata. Phase cannot be inferred from the drug name or regimen comparison. Therefore, the critical phase3_or_definitive criterion is not established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index. PMID 41637791 · Breast · 2026-Apr This is a secondary analysis (prognostic biomarker validation) of two Phase III randomized trials (SOFT/TEXT). While it meets criteria for oncology, human, randomized, time-to-event, and drug intervention, it does not represent a primary report of the trial's efficacy results for a drug-containing intervention. The abstract describes a reclassification of risk groups using a biomarker index, not the primary trial comparison of endocrine therapies. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304). PMID 41633909 · Eur Urol Oncol · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial. PMID 41606119 · Nat Med · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Photodynamic Therapy Plus Topical Corticosteroid for Erosive Oral Lichen Planus: A Randomized Clinical Trial. PMID 41581340 · Int Dent J · 2026-Apr The study is a randomized controlled trial of a drug-containing intervention (photodynamic therapy combined with topical corticosteroid) with primary efficacy outcomes. However, it is excluded because it does not address a human malignant neoplasm (oral lichen planus is a non-malignant inflammatory condition) and lacks the required time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized comparative study of 5-Fluorouracil 4%, tirbanibulin, and photodynamic therapy for relapsing actinic keratoses. PMID 41580230 · Photodiagnosis Photodyn Ther · 2026-Apr The study is a randomized, human, oncology trial with drug intervention and original results, but it lacks a primary or key secondary time-to-event efficacy endpoint as required for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Secondary outcomes of the TROG 99.03 randomized trial of systemic therapy after involved-field radiotherapy in early-stage follicular lymphoma, including toxicity, relapse and second malignancy data. PMID 41580147 · Radiother Oncol · 2026-Apr The record reports secondary outcomes of a randomized trial. While it includes a time-to-event efficacy endpoint (PFS with HR), the abstract and metadata do not explicitly state the trial phase (e.g., Phase III/IIIb). The deterministic review correctly identifies 'phase3_evidence_unclear'. Since the required criterion of a definitive Phase III/IIIb or Phase II/III phase is not explicitly established in the provided text, eligibility cannot be confirmed. The report is also a secondary analysis, not the primary result. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Test results and follow-up care stemming from an ED-based cervical cancer intervention. PMID 41579525 · Am J Emerg Med · 2026-Apr The study is a randomized trial of an ED-based cervical cancer screening intervention, not a drug intervention trial. It lacks the required Phase III/IIIb or Phase II/III drug trial structure and a primary time-to-event efficacy endpoint (like OS or PFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The effect of structured patient-to-patient communication on fear of cancer recurrence in total laryngectomy patients: A randomized controlled trial. PMID 41564457 · Auris Nasus Larynx · 2026-Apr The record describes a randomized controlled trial evaluating a non-drug intervention (patient-to-patient communication) for fear of cancer recurrence in laryngeal cancer patients. It meets oncology, human, and randomized criteria. However, it lacks a drug intervention and a time-to-event efficacy endpoint (like OS, PFS, etc.), which are required for inclusion. The primary endpoints are fear of cancer recurrence (FCRI scores) and swallowing-related quality of life (SWAL-QOL), which are patient-reported outcomes, not survival or time-to-event measures. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Bronchial Arterial Chemoembolization Combined with Tislelizumab for Non-Small Cell Lung Cancer: An Exploratory, Prospective, Single-Arm, Phase II Trial. PMID 41548595 · J Vasc Interv Radiol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Impact of parenteral nutrition on oral intake and eating pleasure in advanced cancer patients: A sub-analysis of a multicenter randomized controlled trial. PMID 41534624 · Clin Nutr ESPEN · 2026-Apr The study is a randomized trial in advanced cancer patients, but it evaluates parenteral nutrition (a non-drug nutritional support) with oral intake and eating pleasure as endpoints. There is no drug intervention and no time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Novel immune-modulating formula versus standard formula for gastrointestinal cancer patients at risk of malnutrition undergoing surgery: A pilot randomized controlled trial. PMID 41525872 · Clin Nutr ESPEN · 2026-Apr The record describes a pilot RCT of a nutritional supplement in gastrointestinal cancer patients. It does not meet the criteria for a Phase II/III or III/IIIb drug trial with a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Trajectory of Neurocognitive Functioning in Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana-Farber Cancer Institute ALL Consortium Study 16-001. PMID 41518030 · Pediatr Blood Cancer · 2026-Apr The study is an oncology Phase III clinical trial in humans with a drug-containing intervention, but it lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS with Kaplan-Meier or HR). The endpoint is neurocognitive functioning, which is a secondary/safety outcome, not a primary efficacy endpoint as required for inclusion. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Post Hoc, Sex-Specific Subgroup Analysis of Efgartigimod in Patients With Generalized Myasthenia Gravis From the ADAPT Trial: A Sex and Gender Equity in Research (SAGER) Guidelines Approach. PMID 41517964 · Muscle Nerve · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of vascular endothelial growth factor inhibitor-induced hypertension on continued cancer treatment: a systematic review and meta-analysis. PMID 41501361 · Hypertens Res · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| RESECT: A Randomised Controlled Trial of Audit and Feedback in Non-muscle-invasive Bladder Cancer Surgery. PMID 41444076 · Eur Urol · 2026-Apr The trial is oncology, human, randomized, and includes a drug intervention (single-instillation chemotherapy) with an original result. However, it is not a Phase III/IIIb or definitive Phase II/III trial (publication type is RCT but phase not specified, and study design is a cluster randomized quality improvement trial, not a drug efficacy trial). Furthermore, the primary endpoints are surgical performance metrics and early recurrence rate (reported as odds ratio), not a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A cost comparison of radiotherapy and topical imiquimod for lentigo maligna treatment: Considerations for clinical decision-making. PMID 41421462 · J Am Acad Dermatol · 2026-Apr The record is a cost-comparison study based on a referenced Phase III randomized trial, but it is not a report of the trial's primary or key secondary time-to-event efficacy endpoint. The abstract focuses on economic outcomes, not survival or progression metrics. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| [18F]-Fluciclovine or [68Ga]-PSMA-11 Molecular Imaging To Guide Dose Escalation of Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer: The EMPIRE-2 Trial. PMID 41412908 · Eur Urol · 2026-Apr The record describes a randomized trial with a primary time-to-event endpoint (EFS) in oncology. However, the intervention is [18F]-fluciclovine or [68Ga]-PSMA-11 for PET-guided radiotherapy dose escalation, which are radiopharmaceuticals used as imaging agents, not therapeutic drugs in the conventional sense of the cohort's definition of 'drug-containing intervention'. Furthermore, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata, making the 'phase3_or_definitive' criterion unestablished. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Re: Niraparib and Abiraterone Acetate plus Prednisone for HRR-deficient Metastatic Castration-sensitive Prostate Cancer: A Randomized Phase 3 Trial. PMID 41407561 · Eur Urol · 2026-Apr The record describes a relevant Phase 3 randomized trial protocol but provides no reported results, including no time-to-event efficacy endpoint data, preventing classification as an eligible original result report. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| The Value of Ultrasound in Patients with T1-T2 Breast Cancer with No Palpable Lymph Nodes Enrolled in the EORTC 10981-22023 AMAROS Trial. PMID 41392224 · Ann Surg Oncol · 2026-Apr The record describes a secondary analysis of the AMAROS trial focusing on the utility of axillary ultrasound. While it is from a Phase III randomized trial in oncology, the analysis is not a primary or key secondary efficacy report with a time-to-event endpoint. The intervention evaluated is a diagnostic procedure (ultrasound), not a drug. Therefore, it does not meet the criteria for inclusion in a Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Diagnostic Accuracy of [18F]FDG PET/CT versus CT for NSCLC Surveillance: Secondary Analysis of a Randomized Clinical Trial. PMID 41387040 · Clin Lung Cancer · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Healthcare Utilization, Costs, and Cost-Effectiveness of Patients Undergoing Laparoscopic and Open Hemihepatectomy: A Secondary Analysis of the ORANGE II PLUS Randomized Controlled, Phase 3, Superiority Trial. PMID 41385067 · Ann Surg Oncol · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Hepatectomy Plus Chemotherapy or Chemotherapy Alone for Resectable Liver and Unresectable Lung Metastases from Colorectal Adenocarcinoma (LUNA): A Randomized Phase II Trial. PMID 41369813 · Ann Surg Oncol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma Group. PMID 41354211 · Ann Oncol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Early adoption patterns of the recombinant zoster vaccine: real-world versus clinical trial populations. PMID 41335379 · Infect Dis (Lond) · 2026-Apr The study is a real-world observational analysis of vaccine uptake and population characteristics, not a clinical trial report. It is not in oncology, does not involve a drug intervention (it's a vaccine), and does not report a time-to-event efficacy endpoint from a randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Effects of Nonintubated Anesthesia onNeutrophil-to-Lymphocyte Ratio and Tumor Markers Among Patients Undergoing Thoracoscopic Lung Resection: A Randomized Controlled Trial. PMID 41320620 · J Cardiothorac Vasc Anesth · 2026-Apr The study is a randomized trial on lung cancer patients, but it evaluates an anesthesia technique (nonintubated vs. traditional) with outcomes focused on inflammatory biomarkers (NLR) and surgical/clinical metrics. It does not involve a drug-containing intervention or a time-to-event efficacy endpoint (e.g., OS, PFS). Therefore, it does not meet the eligibility criteria for the oncology KM digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Under-Representation of Black and Hispanic Men in Metastatic Castration-Resistant Prostate Cancer Trials (2005-2021): A Call to Action. PMID 41284949 · JCO Oncol Pract · 2026-Apr This is a systematic review/meta-analysis of demographic representation in mCRPC trials, not a primary report of a randomized trial with a drug intervention and time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Relationship between [18F]PSMA-1007 PET parameters and biochemical recurrence-free survival in high-risk prostate cancer patients receiving neoadjuvant hormonal treatment. PMID 41231407 · Eur J Nucl Med Mol Imaging · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Preoperative MRI assessment of rectal cancer for predicting metastasis-free survival-a post hoc analysis of a randomized controlled clinical trial. PMID 41162756 · Eur Radiol · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Reply to Mattia Longoni, Giorgio Gandaglia, and Francesco Montorsi's Letter to the Editor re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. 88;2025:510-518. PMID 41136281 · Eur Urol · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Reply to Federico Iori, Emanuele Alì, and Cinzia Iotti's Letter to the Editor re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. 88;2025:88:510-518. PMID 41136279 · Eur Urol · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Huayu Xiaozheng decoction combined with triptorelin and mifepristone in the treatment of uterine fibroids and its effect on uterine artery hemodynamics. PMID 41128268 · Int J Gynaecol Obstet · 2026-Apr While the study is a randomized, human, oncology (uterine neoplasms) trial with a drug intervention and reports original results, it is excluded because the trial phase is not specified as Phase III/IIIb or definitive (Phase II/III), and the primary endpoints are not time-to-event outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Organic Selenium Supplementation on Endometrioma Regression and Pain in Women With Endometriosis: A Triple-Blind Randomized Controlled Clinical Trial. PMID 41073678 · Biol Trace Elem Res · 2026-Apr The study is a randomized, placebo-controlled trial of organic selenium for endometriosis, a non-malignant condition. It evaluates pain scores and cyst size reduction, not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) in human malignant neoplasms. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis. PMID 41033927 · Eur Urol Oncol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term survival analysis of a randomized phase II study of front-line chemo-immunothe-rapy with carboplatin-paclitaxel using oreg-ovomab indirect immunization in advanced ovarian cancer (QPT-ORE-002). PMID 41015763 · Int J Gynecol Cancer · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer. PMID 40774853 · Eur Urol · 2026-Apr The report is an original biomarker/prognostic analysis from a Phase 3 trial, not a primary report of a drug-containing randomized comparison. Therefore, it fails the 'drug_intervention' criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| COVID-19-Related Financial Hardship and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage Breast Cancer. PMID 40525537 · Health Serv Res · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution. PMID 40494733 · Eur Urol Oncol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial. PMID 39613566 · Eur Urol Oncol · 2026-Apr This is a randomized trial in oncology with a time-to-event endpoint (FFTF). However, the analysis is a secondary, pre-specified prognostic biomarker subgroup analysis of nodal status within the main trial, not a primary efficacy report of a drug-containing intervention. The trial evaluated imaging modalities, not a drug intervention, and the analyzed cohort received standard-of-care treatment (surgery/radiotherapy ± androgen deprivation) without comparing different drug regimens. Therefore, it does not meet the criterion of having a drug-containing intervention as the primary variable of interest. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Symptom management interventions influence unscheduled health services use among cancer survivors and caregivers. PMID 39612086 · J Cancer Surviv · 2026-Apr Study is a randomized trial in cancer survivors but the intervention is non-drug (telephone symptom management and counseling) and the primary endpoint is healthcare utilization (ED/urgent care visits), not a time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it does not meet the criteria for inclusion in the KM digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pilot Testing of Build StaMINA: A Tailored Physical Activity Program for Adults Receiving Treatment for Acute Myeloid Leukemia. PMID 40203204 · Cancer Nurs · 2026 May The study is a randomized oncology trial in humans but is a pilot/feasibility study (not Phase III or definitive Phase II/III) with a non-drug intervention (physical activity) and a primary outcome of physical function (6-Minute Walk Distance), not a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |